Not a dumb question. I would say it has a binary element in terms of "failure" i.e. there is no significant difference in outcome between the treated patients and the placebo controls. However there are varying grades of "success", from all the treated patents showing significant improvement in symptoms (maybe the equivalent of 5 years of disease progression) to only the last cohort showing halting of progression. But there are a lot of combinations in between.
Ann: LCT files pericyte protective agent provisional patent, page-30
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.49M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.9¢ | 0.8¢ | $4.381K | 538.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 7370761 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 978986 | 4 |
View Market Depth
| Last trade - 15.59pm 25/07/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |